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Susceptibility genes of asthmamay bemore successfully identified by studying subgroups of phenotypically similar asthma patients.
This study aims to identify single nucleotide polymorphisms (SNPs) associated with asthma in French Canadian adult women. A
pooling-based genome-wide association study was performed in 240 allergic asthmatic and 120 allergic nonasthmatic women.The
top associated SNPs were selected for individual genotyping in an extended cohort of 349 asthmatic and 261 nonasthmatic women.
The functional impact of asthma-associated SNPs was investigated in a lung expression quantitative trait loci (eQTL) mapping
study (𝑛 = 1035). Twenty-one of the 38 SNPs tested by individual genotyping showed 𝑃 values lower than 0.05 for association
with asthma. Cis-eQTL analyses supported the functional contribution of rs17801353 associated with C3AR1 (𝑃 = 7.90𝐸 − 10).
The asthma risk allele for rs17801353 is associated with higher mRNA expression levels of C3AR1 in lung tissue. In silico functional
characterization of the asthma-associated SNPs also supported the contribution of C3AR1 and additional genes including SYNE1,
LINGO2, and IFNG-AS1. This pooling-based GWAS in French Canadian adult women followed by lung eQTL mapping suggested
C3AR1 as a functional locus associated with asthma. Additional susceptibility genes were suggested in this homogenous subgroup
of asthma patients.
1. Introduction
Substantial efforts have been deployed to discover the genetic
variants associated with asthma [1, 2]. Asthma constitutes
a considerable burden for individuals and health services
with more than 300 million persons affected worldwide [3].
Various approaches have been used to identify asthma risk
loci and genome-wide association studies (GWASs) have
discovered the most robust genetic associations [4, 5]. This
genomic approach still requires substantial resource in terms
of sample size and genotyping. To reduce the genotyping
burden, an alternative methodology has been developed,
which consists of a GWAS on pooled DNA samples (pooled
GWAS) followed by further validation of the top associations
by individual genotyping. This approach has been shown to
be effective for several complex traits [6]. It has also been
applied to asthma and has confirmed known asthma loci and
led to the identification of new ones [7, 8].
GWAS SNPs discovered so far account for a relatively
low percentage of the total asthma heritability. Studying
more homogeneous subgroups of asthma patients is likely
to reveal part of this “missing heritability.” The rationale is
that individuals within subgroups are more likely to share the
same underlying molecular basis. It is known that asthma
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Figure 1: Overview of the experimental design.
prevalence differs between men and women throughout
life [9]. This sex difference is not completely understood.
Studying the genetics of asthma by gender and age groups is
thus important [10].
In this study, we used a pooled GWAS to detect SNPs
associated with asthma in French Canadian women enrolled
in the Quebec City Case-Control Asthma Cohort (QCC-
CAC). Confirmation by individual genotyping was followed
by analyses of expression quantitative trait loci (eQTL) in
human lung tissues, in silico analyses for functional predic-
tion and validation in a second collection of FrenchCanadian
women.
2. Methods
The experimental design is summarized in Figure 1.
2.1. Participants. Cases and controls included in this study
are part of the Quebec City Case-Control Asthma Cohort
[11]. Briefly, the QCCCAC consists of unrelated adults of
self-reported European ancestry recruited at the research
center of the Institut Universitaire de Cardiologie et de
Pneumologie de Que´bec (IUCPQ). All research participants
were ≥18 years old at enrollment. Individuals with chronic
obstructive pulmonary disease (COPD), body mass index
>40 kg/m2, and/or any systemic inflammatory disease were
excluded. Individuals with self-reported genetic relatedness
were also excluded. Participants provided written informed
consent and the study was approved by the ethics committee
of the IUCPQ. For the current study, only women were
investigated and the asthma diagnosis was confirmed by
a respirologist based on clinical symptoms, lung function,
and airway responsiveness. Twenty-five inhalant allergens
were evaluated by skin-prick tests to measure the allergic
status. Participants were considered atopic if at least one
allergen caused a wheal diameter of at least 3mm at 10min
in the presence of a negative saline control and a positive
histamine response. Asthma-associated SNPs were tested for
replication inwomen participants of the Saguenay-Lac-Saint-
Jean (SLSJ) asthma family collection (𝑛 = 353). Further
details are provided in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/3564341.
2.2. Pooled GWAS and Analysis. DNA extraction and sample
pooling methods are provided in Supplementary Material.
Both pools (i.e., cases and controls) were genotyped in 6
replicates using the Illumina HumanOmniExpress Bead-
Chip (Supplementary Figure 1). This SNP array interrogated
730,525 SNPs throughout the genome.The SNP array probes’
intensities were formatted and analyzed by the GenePool
software [12]. GenePool ranked SNPs by increased likelihood
of being genetically associated with asthma. To do so, the
Manhattan distance method and the silhouette score cluster-
ing method were used as implemented in GenePool. Each
SNP was assigned a silhouette score that ranged from 0 to
1. A silhouette score of 1 indicates that the allele frequencies
for a specific SNP are unequivocally different between cases
and controls. Further details are provided in Supplementary
Material.
2.3. Individual Genotyping and Genetic Association Tests.
Following the pooled GWAS, a total of 43 SNPs were selected
for validation by individual genotyping. First, the 20 SNPs
with the best silhouette score were included. Then, SNPs
ranked in the top 2000 of the pooled GWAS and found in or
near (50 kb) genes previously associated with asthma, COPD,
or related phenotypes in candidate gene studies and GWAS
were selected [2, 13]. This resulted in 23 additional SNPs
for validation by individual genotyping. Selected SNPs (𝑛 =
43) were genotyped in an extended cohort of 349 asthmatic
women and 261 nonasthmatic women derived from the
QCCCAC. This extended cohort contained the women used
in the pooled GWAS. Genotyping and quality controls are
provided in Supplementary Material. After quality control,
38 out of the 43 SNPs remained. Association tests were done
using additive logistic regression models as implemented in
PLINK v1.07 [14]. Analyses were first performed in allergic
cases (𝑛 = 299) and allergic controls (𝑛 = 154) women
to mirror the selection of individuals used in the pooling-
based GWAS. Analyses were then repeated in all available
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cases (𝑛 = 349) and controls (𝑛 = 261) women with
or without allergy in an attempt to increase sample size
and evaluate the specificity of genetic signals. 𝑃 value <0.05
was considered suggestive evidence of association. 𝑃 value
that passed Bonferroni correction (0.05/38 = 0.0013) was
considered statistically significant.
2.4. eQTL and In Silico Analyses. The functional effects of
the asthma-associated SNPs were determined by examining
their effect on gene expression in human lung tissue. The
lung expression quantitative trait loci (eQTL) mapping study
has been previously described [15, 16]. Briefly, 1111 lung
specimens were obtained from patients who underwent
lung resection at three sites: Laval University (Quebec City,
Canada), University ofGroningen (Groningen,Netherlands),
and University of British Columbia (Vancouver, Canada).
Whole-genome gene expression and genotyping data were
obtained from these specimens. The genotyping platform
used in the eQTL dataset is the Illumina Human1M-Duo
BeadChip. The imputation was performed with SHAPEIT
v2 and IMPUTE v2 using the 1000-genome project phase 1
data as a reference set. In the present study, SNPs associated
with asthma, including SNPs in linkage disequilibrium (LD),
were tested for association with gene expression in the Laval
dataset (𝑛 = 407). Replication was then performed in the
Groningen (𝑛 = 341) and UBC (𝑛 = 287) cohorts. In silico
analyses were also performed to investigate the functional
impact of asthma-associated SNPs. Tools used in this study
are Combined-Annotation-Dependent Depletion (CADD)
V1.3 [17], SNP Function Prediction (FuncPred) [18], Regu-
lomeDB V1.1 [19], and Haploreg V4 [20]. Further details are
provided in Supplementary Materials.
3. Results
3.1. Subjects. A total of 240 asthma patients and 120 controls
were considered in the pooled GWAS. All subjects were
atopic women with mean age of 34.0 ± 13.9 years for cases
and 35.2 ± 14.3 years for controls, respectively. Individual
genotyping was performed in an extended cohort of 349
asthmatic women and 261 controls. Clinical characteristics
are summarized in Table 1.
3.2. Pooled GWAS. Genotyping data from DNA pools were
analyzed with the GenePool software. All SNPs were ranked
according to the likelihood of being genetically associated
with asthma using the silhouette score (Figure 2). The
top 20 SNPs selected for individual genotyping are shown
in Table 2 and ranked by the silhouette score. One SNP,
rs17093106, failed the Illumina design assay step for indi-
vidual genotyping and was replaced by the 21st top SNP,
rs17500510. The SNP rs12418753 was ranked first with a
silhouette score of 0.709. The silhouette scores in Table 2
ranged from 0.636 to 0.709. All SNPs were located in
noncoding regions except SNP rs12881815 located in an
exon of the SYNE2 gene. None of these SNPs had been
previously associated with asthma. Twenty-three additional
SNPs located near orwithin asthma candidate geneswerewell
ranked (i.e., top 2000) and selected for individual genotyping
(Table 3).
3.3. Individual Genotyping. From the 43 selected SNPs that
were typed by individual genotyping, 38 passed quality
controls. For the top 20 ranked SNPs in the pooled GWAS,
18 SNPs passed the quality controls. The genotyping assay
failed for the only exonic SNP, rs12881815, and for rs12493799.
For the 23 SNPs near candidate genes among the top 2000
ranked SNPs, 20 passed the quality controls.
The association with asthma was first tested in atopic
women only tomirror the selection of women included in the
pooled GWAS. Associations with asthma were suggestive for
29 SNPs out of 38 (76%) and 7 of them were significant after
Bonferroni correction (Supplementary Table 1). All 7 SNPs
were part of the top ranked SNPs in the pooledGWAS. For the
SNPs located near candidate genes and among the top 2000
ranked SNPs, 13 showed a suggestive evidence of association.
Overall, only 9 SNPs had 𝑃 values >0.05, ranging from 0.06
to 0.23.
The same 38 SNPs were then tested in an extended cohort
containing all available cases and controls women genotyped
in the QCCCAC. Twenty-one out of the 38 SNPs (55%)
demonstrated suggestive associations with asthma (Table 4).
Three SNPs were significant after correction for multiple
testing including two from the top ranked SNPs and one
from the SNPs near candidate genes. Association tests were
also performed in 255 men (213 cases, 142 controls) of the
QCCCAC and all suggestive associations were stronger in
women compared to men (Supplementary Figure 2).The two
strongest associations involved two SNPs newly implicated in
asthma, rs17655581 and rs7980829, located near SLC15A1 and
in an intergenic region, respectively. In general, new SNPs
identified in the top of the pooled GWAS showed stronger
associations with asthma compared to those selected due to
their proximity to candidate genes. However, three SNPs near
candidate genes were part of the strongest associations. They
were rs803010 near PTGDR and PTGER2, rs10932034 near
ICOS, and rs17453235 near DPP10. Results for the 21 SNPs
with 𝑃 < 0.05 for association with asthma and those in LD
are detailed in Supplementary Table 2, including information
on the genomic context, the LDmapping, the pooled GWAS,
the individual genotyping in all case and control women,
the replication in SLSJ family collection, and the in silico
functional prediction.
3.4. Lung eQTL Analyses. To investigate the potential func-
tion of SNPs associated with asthma in the QCCCAC, we
analyzed a large-scale lung eQTL dataset [15]. SNPs in LD
(𝑛 = 309) with the 21 asthma-associated SNPs were tested in
the eQTL dataset. Fifty-five out of these SNPswere genotyped
in the lung eQTL dataset and the genotype information for
the remaining SNPs was obtained by imputation. Each of
themwas tested against the expression levels of all noncontrol
probesets interrogated by the gene expressionmicroarray (𝑛=
51,627).Themost significant lung eQTL-SNP was rs75871129,
which passed the Bonferroni correction for multiple testing
threshold (3.1𝐸 − 9) and was associated with a probeset
4 Canadian Respiratory Journal
Ta
bl
e
1:
Cl
in
ic
al
ch
ar
ac
te
ris
tic
so
fw
om
en
.
Ch
ar
ac
te
ris
tic
s
Po
ol
ed
G
W
A
S
In
di
vi
du
al
ge
no
ty
pi
ng
SL
SJ
as
th
m
af
am
ily
co
lle
ct
io
n
Ca
se
s(
𝑛
=
2
4
0
)
C
on
tro
ls
(𝑛
=
1
2
0
)
𝑃
va
lu
es
Ca
se
s(
𝑛
=
3
4
9
)
C
on
tro
ls
(𝑛
=
2
6
1
)
𝑃
va
lu
es
Ca
se
s(
𝑛
=
2
3
3
)
C
on
tro
ls
(𝑛
=
1
2
0
)
𝑃
va
lu
es
A
ge
(y
ea
rs
)
34
.0
±
13
.9
35
.2
±
14
.3
0.
45
6
35
.5
±
14
.8
36
.0
±
14
.8
0.
69
1
30
.6
±
17.
8
40
.6
±
19
.4
<
0.
00
01
BM
I(
kg
/m
2
)
25
.3
±
4.
8
24
.4
±
4.
1
0.
06
6
25
.9
±
5.
4
24
.5
±
4.
5
0.
00
1
24
.5
±
6.
8
24
.4
±
6.
0
0.
88
7
FE
V
1
(%
pr
ed
ic
te
d)
95
.1
±
16
.5
10
5.
6
±
11
.7
<
0.
00
01
94
.4
±
17.
2
10
6.
4
±
12
.2
<
0.
00
01
92
.5
±
16
.3
10
0.
8
±
14
.2
<
0.
00
01
FV
C
(%
pr
ed
ic
te
d)
10
7.5
±
14
.6
11
1.0
±
12
.9
0.
02
1
10
6.
5
±
15
.3
11
1.6
±
13
.4
<
0.
00
01
99
.6
±
15
.9
10
5.
4
±
15
.9
0.
00
1
A
H
R
(p
os
iti
ve
:n
eg
at
iv
e:
N
A
)
18
9:
33
:1
8
11
:1
09
:0
<
0.
00
01
25
8:
55
:3
6
25
:2
33
:3
<
0.
00
01
10
8:
29
:9
6
18
:4
2:
60
<
0.
00
01
Bl
oo
d
Ig
E
(U
I/m
L)
32
1.7
±
93
5.
8
13
3.
3
±
25
2.
1
<
0.
00
01
27
9.3
±
80
8.
9
87
.0
±
19
0.
6
<
0.
00
01
60
6.
7
±
10
89
.9
23
1.5
±
37
5.
8
<
0.
00
01
Bl
oo
d
eo
sin
op
hi
ls
(%
)
3.
6
±
2.
6
2.
4
±
1.6
<
0.
00
01
3.
4
±
2.
5
2.
2
±
1.6
<
0.
00
01
3.
8
±
2.
7
2.
7
±
1.7
<
0.
00
01
At
op
y
(p
os
iti
ve
:n
eg
at
iv
e:
N
A
)
24
0:
0:
0
12
0:
0:
0
<
0.
00
01
29
9:
46
:4
15
4:
10
7:
0
<
0.
00
01
22
1:
0:
12
11
1:
0:
9
<
0.
00
01
Sm
ok
in
g
sta
tu
s(
𝑛
)[
%
]
N
on
sm
ok
er
16
6
[6
9.2
]
85
[7
0.
8]
0.
00
1
22
5
[6
4.
5]
19
0
[7
2.
8]
0.
00
2
15
5
[6
6.
5]
54
[4
5.
0]
0.
00
1
Ex
-s
m
ok
er
69
[2
8.
7]
23
[19
.2
]
110
[3
1.5
]
52
[19
.9
]
37
[1
5.
9]
33
[2
7.5
]
Sm
ok
er
5
[2
.1]
12
[1
0.
0]
14
[4
.0
]
19
[7.
3]
37
[1
5.
9]
29
[2
4.
2]
BM
I,
bo
dy
m
as
si
nd
ex
;F
EV
1,
fo
rc
ed
ex
pi
ra
to
ry
vo
lu
m
ei
n
1s
ec
on
d;
FV
C,
fo
rc
ed
vi
ta
lc
ap
ac
ity
;A
H
R,
ai
rw
ay
hy
pe
rr
es
po
ns
iv
en
es
s,
de
fin
ed
as
pr
ov
oc
at
iv
ec
on
ce
nt
ra
tio
n
of
m
et
ha
ch
ol
in
ei
nd
uc
in
ga
20
%
fa
ll
in
FE
V
1
(P
C2
0)
<
8m
g/
m
L;
an
d
Ig
E,
im
m
un
og
lo
bu
lin
E.
C
on
tin
uo
us
va
ria
bl
es
ar
ee
xp
re
ss
ed
as
m
ea
n
±
SD
.𝑃
va
lu
es
w
er
ec
al
cu
lat
ed
us
in
g
𝑡
-te
st
or
ch
i-s
qu
ar
et
es
ts
as
ap
pr
op
ria
te
.
Canadian Respiratory Journal 5
0
E
+
0
0
1
E
+
0
8
2
E
+
0
8
0
E
+
0
0
1
E
+
0
8
2
E
+
0
8
0
E
+
0
0
5
E
+
0
7
1
E
+
0
8
0
E
+
0
0
5
E
+
0
7
1
E
+
0
8
0
E
+
0
0
5
E
+
0
7
1
E
+
0
8
0
E
+
0
0
5
E
+
0
7
1
E
+
0
8
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
2
.0
E
+
0
8
0
.0
E
+
0
0
0
.0
E
+
0
0
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
0
.0
E
+
0
0
0
.0
E
+
0
0
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
0
.0
E
+
0
0
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
0
.0
E
+
0
0
5
E
+
0
7
1
E
+
0
8
5
E
+
0
7
1
E
+
0
8
2
E
+
0
7
4
E
+
0
7
6
E
+
0
7
8
E
+
0
7
1
E
+
0
8
0
E
+
0
0
5
E
+
0
7
0
E
+
0
0
2
E
+
0
7
4
E
+
0
7
6
E
+
0
7
8
E
+
0
7
0
E
+
0
0
2
E
+
0
7
4
E
+
0
7
6
E
+
0
7
PositionPositionPosition
1 2 3
4 5 6
7 8 9
10 11 12
13 14 15
16 17 18
Figure 2: Continued.
6 Canadian Respiratory Journal
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
−5
−4
−3
−2
−1
0
−
lo
g 
ra
nk
0
E
+
0
0
2
E
+
0
7
4
E
+
0
7
6
E
+
0
7
0
E
+
0
0
2
E
+
0
7
4
E
+
0
7
6
E
+
0
7
2
E
+
0
7
3
E
+
0
7
4
E
+
0
7
2
E
+
0
7
3
E
+
0
7
4
E
+
0
7
5
E
+
0
7
0
.0
E
+
0
0
5
.0
E
+
0
7
1
.0
E
+
0
8
1
.5
E
+
0
8
PositionPosition
19 20 21
22 X
Figure 2: Genome-wide plot of the silhouette scores for the top 100,000 SNPs. The chromosome number is indicated on the top of each
subgraph. The 𝑦-axis represents the silhouette score ranking on a log scale and the 𝑥-axis indicates the position of the SNPs in physical
distance.
interrogating C3AR1 (𝑃 = 4.06𝐸 − 10). The SNP was in
perfect LDwith the asthma-associated SNP rs17801353,which
had a similar association with mRNA C3AR1 levels (𝑃 =
7.90𝐸 − 10). All the SNPs in this LD block (𝑅2 > 0.8) were
also associated with mRNA expression of C3AR1 in the lung.
Figure 3 illustrates the lung eQTL rs17801353-C3AR1 in Laval
as well as replications in Groningen and UBC. rs17801353 is
located in an intron of FOXJ2 7.6 kb downstream of C3AR1.
The eQTL was significant and showed the same direction of
effect in the two replication cohorts (𝑃 < 0.05). The asthma
risk allele for rs17801353 in the QCCCAC corresponds to
the allele associated with higher mRNA expression levels for
C3AR1, suggesting that upregulation of this genemay increase
asthma susceptibility. The most significant lung eQTL (𝑃 <
10𝐸 − 5) are shown in Supplementary Table 3.
3.5. In Silico Functional Characterization. We investigated if
any of the LD SNPs were potentially implicated in regulatory
mechanisms using bioinformatics tools. First, we employed
CADD to score the deleteriousness of the 309 LD SNPs. A
scaled 𝐶-score higher than 10 was obtained for twenty-five
of them, indicating that they are predicted to be in the
10% most deleterious genetic variants of the human genome.
Of these 25 SNPs, six are part of LD block located in an
intronic region of the gene LINGO2 on chromosome 9p21.1.
SNP rs2295190 located on chromosome 6q25.1 showed the
greatest scaled 𝐶-score (24.5), implying that it is among the
top 0.5% most deleterious SNPs of the human genome. This
SNP is in LD with rs6934016 located near the ESR1 asthma
susceptibility gene. The scaled 𝐶-score of each LD SNP is
shown in Supplementary Table 2.
The FuncPred software recognised 184 out of the
309 LD SNPs and revealed regulatory predictions (Supple-
mentary Table 4). The intronic SNP rs13081182 showed the
strongest regulatory potential score (0.406). This SNP is in
LD (𝑅2 = 0.94) with SNP rs17016738 associated with asthma
in this study (Table 4). The nonsynonymous SNP rs2295190
also showed a strong regulatory potential score (0.395) and
is implicated in splicing events. Located in SYNE1, this SNP
was found to be probably damaging for SYNE1 based on
PolyPhen v2 with a score of 0.994/1.00 (sensitivity: 0.69;
specificity: 0.97). This SNP is in LD (𝑅2 = 0.85) with SNP
rs6934016 associated with asthma in this study (Table 4).The
asthma risk allele (A) for rs2295190 corresponds to amissense
change that occurs at position 8741 of the protein (L8741M).
The FuncPred tool also revealed SNPs with high regulatory
potential scores in the LD block located in an intronic region
of gene LINGO2 on chromosome 9p21.1, the same LD block
mentioned above with several high scaled 𝐶-score SNPs.
The RegulomeDB V1.1 attributed a valid score to
276 LD SNPs according to the number of regulatory elements
they influence (Supplementary Table 5). Two SNPs in the
same haplotype block of chromosome 12p13.31, rs10846377
and rs7955798, were ranked highest with important sup-
porting data. The regulatory prediction for rs10846377 was
supported by data including eQTL, transcription factor
binding, any motif, and DNase peak score. rs7955798 was
supported by eQTL and transcription factor binding/DNase
peak.These two SNPswere associatedwithmRNAexpression
levels of C3AR1 in circulating monocytes [21]. Both SNPs
are in the same haplotype block identified by the lung
eQTL analyses. Furthermore, the second most significant
association following individual genotyping, rs7980829, was
ranked third in the scores attributed by RegulomeDB V1.1.
Many motifs are predicted to be altered by this variant and it
is thus likely to affect binding of transcription factors in this
region.
Canadian Respiratory Journal 7
Table 2: The top 20 ranked SNPs in the pooled GWAS.
dbSNP ID Chromosome Silhouette score Gene Position
rs12418753 11p15.4 0.709 NLRP14 5󸀠UTR
rs4487406 4q28.3 0.694 Intergenic
rs17655581 13q32.3 0.692 Intergenic
rs5904772 Xq27.3 0.689 Intergenic
rs11134480 5q34 0.686 ODZ2 Intronic
rs12881815 14q23.2 0.669 SYNE2 Exonic
rs12629883 3q28 0.666 Intergenic
rs10968574 9p21.1 0.661 LINGO2 Intronic
rs11600687 11q25 0.658 Intergenic
rs7980829 12q15 0.655 Intergenic
rs11956185 5q35.2 0.654 Intergenic
rs12070470 1p31.3 0.648 IL23R Intronic
rs739337 8p22 0.647 MTMR7 Intronic
rs5970666 Xp22.11 0.646 Intergenic
rs881754 11q24.1 0.646 Intergenic
rs12493799 3q27.3 0.646 Intergenic
rs4808611 19p13.11 0.646 NR2F6 Intronic
rs7896493 10p14 0.644 Intergenic
rs2335562 13q12.12 0.643 Intergenic
rs17500510 6p21.32 0.636 HLA DQA2 Intronic
Table 3: SNPs ranked in the top 2000 of the pooled GWAS that are near or within asthma candidate genes and selected for individual
genotyping.
dbSNP ID Chromosome Rank∗ Silhouette score Near candidate gene(s)
rs7576929 2q35 56 0.618 SLC11A1
rs3094738 6p21.33 85 0.593 MICB
rs6934016 6q25.1 100 0.585 ESR1
rs5250 14q12 115 0.577 CMA1
rs17016738 3p24.2 220 0.544 RARB
rs17453235 2q14.1 290 0.531 DPP10
rs7131715 12q13.12 305 0.528 AQP5
rs3097657 6p21.32 371 0.517 HLA-DPB1
rs2071596 6p21.33 373 0.517 LTA, MICB, NCR3, TNF
rs2858769 Xp11.23 515 0.502 TIMP1
rs9874200 3q26.2 562 0.497 MECOM
rs10932034 2q33.2 567 0.497 ICOS
rs2904774 6p21.33 601 0.494 MICB
rs17466945 1q32.1 626 0.492 CHI3L1
rs803010 14q22.1 723 0.484 PTGDR, PTGER2
rs1889371 14q32.2 742 0.482 BDKRB2
rs10864910 2q13 786 0.479 IL1RN
rs241423 6p21.32 811 0.478 TAP1
rs17160155 11q13.5 881 0.473 LRRC32
rs3135195 6p21.32 961 0.468 HLA-DPB1
rs3093665 6p21.33 970 0.467 AIF1, LTA, NCR3, TNF
rs17801353 12p13.31 981 0.466 C3AR1
rs6657275 1q41 1017 0.464 TGFB2
∗Ranking based on the pooled GWAS.
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Table 4: Genetic association results for 38 SNPs tested by individual genotyping in 349 cases and 261 controls.
dbSNP ID Chromosome Minor allele Freq in cases∗ Freq in controls∗ Major allele 𝑃 value† Odd ratio
rs17655581 13q32.3 G 0.02 0.07 A 8𝐸 − 05 0.32
rs7980829 12q15 A 0.13 0.21 C 2𝐸 − 04 0.57
rs803010 14q22.1 A 0.30 0.21 G 4𝐸 − 04 1.60
rs10932034 2q33.2 A 0.25 0.17 G 0.001 1.59
rs10968574 9p21.1 G 0.10 0.05 A 0.002 2.07
rs17453235 2q14.1 G 0.13 0.08 A 0.005 1.71
rs12070470 1p31.3 G 0.12 0.07 A 0.005 1.78
rs881754 11q24.1 G 0.12 0.08 A 0.007 1.71
rs739337 8p22 G 0.05 0.02 A 0.008 2.54
rs11134480 5q34 G 0.13 0.09 A 0.012 1.61
rs17500510 6p21.32 A 0.14 0.09 G 0.018 1.55
rs2904774 6p21.33 G 0.03 0.01 A 0.019 3.43
rs7896493 10p14 A 0.13 0.09 G 0.019 1.55
rs6934016 6q25.1 A 0.14 0.10 C 0.020 1.53
rs12418753 11p15.4 A 0.04 0.02 G 0.021 2.30
rs3093665 6p21.33 C 0.03 0.01 A 0.021 2.62
rs17016738 3p24.2 A 0.30 0.24 G 0.023 1.35
rs17801353 12p13.31 C 0.40 0.34 A 0.028 1.30
rs9874200 3q26.2 G 0.11 0.07 A 0.029 1.58
rs5904772 Xq27.3 G 0.14 0.10 A 0.029 1.49
rs10864910 2q13 A 0.14 0.18 G 0.033 0.72
rs12629883 3q28 G 0.02 0.01 A 0.055 2.58
rs11956185 5q35.2 G 0.10 0.07 A 0.071 1.48
rs5250 14q12 A 0.13 0.09 G 0.082 1.39
rs6657275 1q41 G 0.32 0.27 A 0.088 1.24
rs3094738 6p21.33 G 0.08 0.06 A 0.099 1.47
rs3135195 6p21.32 C 0.06 0.04 A 0.129 1.53
rs7131715 12q13.12 G 0.09 0.07 A 0.130 1.39
rs4487406 4q28.3 G 0.08 0.06 A 0.190 1.36
rs3097657 6p21.32 G 0.05 0.04 A 0.190 1.45
rs2335562 13q12.12 A 0.18 0.16 G 0.218 1.21
rs5970666 Xp22.11 G 0.04 0.03 A 0.307 1.41
rs241423 6p21.32 A 0.04 0.06 G 0.311 0.76
rs4808611 19p13.11 A 0.17 0.15 G 0.312 1.17
rs17466945 1q32.1 C 0.11 0.09 A 0.316 1.22
rs2071596 6p21.33 A 0.15 0.14 G 0.453 1.13
rs17160155 11q13.5 G 0.14 0.12 A 0.488 1.13
rs11600687 11q25 A 0.09 0.09 G 0.774 1.06
∗Minor allele frequency in cases and controls.
†Sorted by 𝑃 values.
The Haploreg V4 software recognised 283 out of the
309 LD SNPs and indicated that several LD SNPswere associ-
ated with mRNA expression levels (Supplementary Table 6).
The rs7980829 and rs11177020 have been previously associ-
ated with themRNA expression levels of IFNG-AS1 in various
tissues including lymphoblastoid cell lines of Europeans. The
LD SNPs on chromosome 12p13.31 were also shown to be
associated with mRNA expression levels of C3AR1 in whole
blood.
3.6. Validation in the SLSJ Asthma Family Collection. To
confirm the genetic associations detected in the QCCCAC,
the 21 asthma-associated SNPs were analyzed in the SLSJ
asthma study. Clinical characteristics of cases and controls
are indicated in Table 1. Eleven out of the 21 SNPs were
directly genotyped. None of these SNPs was associated with
asthma (Supplementary Table 7). The lowest 𝑃 value for
associationwith asthmawaswith rs17016738 (𝑃 = 0.080).The
remaining 10 SNPs were tested with proxies if available. None
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Figure 3: Boxplots of lung mRNA expression levels for C3AR1 according to genotype groups for SNP rs17801353 in lung tissues from Laval
(𝑛 = 407), Groningen (𝑛 = 341), and UBC (𝑛 = 287). The right 𝑦-axis shows the proportion of the gene expression variance explained by the
SNP (black bar). The 𝑥-axis represents the three genotyping groups for SNP rs17801353 with the number of subjects in parenthesis.
of them showed association with asthma (Supplementary
Table 8).
4. Discussion
This pooled GWAS was performed on a relatively homoge-
neous subgroup of asthma patients defined by age, atopic sta-
tus, ethnicity, and gender (i.e., adult, atopic, French Canadian
women with doctor diagnosed asthma). Several loci were
associated with asthma and confirmed by individual geno-
typing in an extended sample of French Canadian women.
The functional meaning of asthma-associated SNPs was then
evaluated in a large lung eQTL study, which supported
C3AR1 as an asthma susceptibility gene. In silico analyses also
supported C3AR1 as well as additional genes neighbouring
functional asthma-associated SNPs.
Several GWASs have been performed to study the genet-
ics of asthma [4, 5]. GWAS revealed numerous susceptibility
loci that explain only a small fraction of the total asthma her-
itability. GWASs have the potential to reveal additional loci
using extended study design [22]. Studying subgroups of phe-
notypically similar asthma patients instead of the traditional
broad case-control format may reveal new susceptibility loci.
Using this strategy, Bønnelykke et al. identified CDHR3 as
a new susceptibility gene in childhood asthma with severe
exacerbations [23]. Similarly, we used a homogeneous sub-
group of asthma patients. Pooled genotyping was used as it
is an economic approach to perform a preliminary screen
for evidence of association. As recommended, this screen
was followed by individual genotyping for confirmation [24].
SNPs identified with the pooled GWAS were in large part
(76%) validated by individual genotyping in atopic women.
This pooling-based approach has been used previously to
study asthma and new risk loci were identified [7, 8]. These
two studies were conducted in allergic asthmatic children
of white European descent and in a Chinese population,
respectively. None of their findings were replicated in this
study, which is likely explained by clinical, demographic, and
genetic differences.
In this study, one functional SNP located 7.6 kb from
C3AR1was associated with asthma. rs17801353 was associated
with asthma in the extended case-control sample (𝑃 =
0.028). Lung eQTL analysis demonstrated that rs17801353 is
associated with expression levels of C3AR1. This SNP was
selected for individual genotyping owing to its proximitywith
that candidate gene on chromosome 12p13.31. This eQTL is
reported for the first time in lung tissue and demonstrated
the functionality of rs17801353. However, in silico analyses
identified a study conducted in circulating monocytes where
two SNPs in LD with rs17801353 were found to act as eQTL
for C3AR1 [21]. C3AR1 is involved in the pathogenesis of
asthma via the complement system [25, 26]. The expression
of this receptor is increased during asthmatic lung inflam-
mation [27]. The same direction of effect is observed in the
current study as the asthma risk allele increased the mRNA
expression levels of C3AR1 in the three cohorts, which is also
consistent with the study on circulating monocytes.
The two strongest associations with asthma after individ-
ual genotyping in the QCCCAC were with rs17655581 and
rs7980829.The first one is located on chromosome 13q32.3 at
5.1 kb 3󸀠 of SLC15A1.This SNP received no clear prediction for
putative function from the bioinformatic tools employed and
was not implicated in any significant eQTL.The closest gene,
SLC15A1, is not known to be involved in asthma but is known
to cause inflammation in the intestine by the mediation of
intracellular uptake of bacterial products [28]. For rs7980829,
located on chromosome 12q15, RegulomeDB V1.1 predicted
that this SNP may influence protein binding. Furthermore,
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Haploreg V4 showed that the SNP is associated with the long
intergenic noncoding RNA (lincRNA) expression levels of
IFNG-AS1. This lincRNA has been shown to influence and
regulate the expression of IFNG [29, 30]. Interestingly, IFNG
is an inflammatory cytokine implicated in the pathophysiol-
ogy of asthma [31].
One LD block located in an intronic region of the gene
LINGO2 on chromosome 9p21.1 contained the most poten-
tially deleterious SNPs predicted by in silico analyses. This
leucine-rich repeat and Ig domain-containing 2 (LINGO2)
gene is not known to be implicated in asthma. A recent
study found that SNPs flanked by LINGO2 were associated
with airway responsiveness in chronic obstructive pulmonary
disease [32]. These SNPs are not in LD with any of the SNPs
in the LD block identified in this study (all 𝑅2 < 0.05).
Among the LD SNPs, only rs2295190 was located in
an exon and PolyPhen 2 predicted this missense variant
as probably damaging for SYNE1. The asthma risk allele
for rs6934016 (A) identified by individual genotyping corre-
sponds to the allele in LD with SNP rs2295190 (T) producing
a missense change. SYNE1 has never been associated with
asthma, but two intronic SNPs of this gene have been asso-
ciated with forced vital capacity according to the Phenotype-
Genotype Integrator (PheGenI) [33]. SYNE1 is expressed in
skeletal and smooth muscle, particularly in the sarcomeres
[34]. Thus, SYNE1 could potentially have an effect on airway
smoothmuscle and influencemuscle function during asthma
attacks. Interestingly, one missense SNP in a related gene,
SYNE2, was significant in the pooled GWAS but failed
individual genotyping. SYNE1 and SYNE2 are known to
be implicated in several diseases such as lung cancer [35].
Their role in the physiopathology of asthma remains to be
confirmed.
Associations were revealed with SNPs among the top
2000 ranked SNPs and near candidate genes. The third most
important association with asthma was found with rs803010
(𝑃 = 4.4 × 10−4) located in the promoter of the prostaglandin
D2 receptor (PTGDR). This gene is known to be involved
in asthma in Caucasian populations [36, 37]. PTGDR is
activated by PGD
2
and leads to an increase of intracellular
cAMP [38]. This augmentation is notably associated with
more pronounced Th2 inflammation [39]. PTGDR may be
implicated in bronchial hyperreactivity since knockout mice
(Ptgdr−/−) are protected against ovalbumin-induced hyperre-
activity [40].
Genetic associations observed in the QCCCAC were not
replicated in SLSJ asthma family collection. This could be
partly due to the relatively small sample size of both datasets.
Attempt to replicate was worthy as these two cohorts share
similar age, asthma definition, and genetic background (both
being French Canadian). The analyses were also restricted
to women. However, asthma heterogeneity, not captured by
our study design, may also be responsible for the lack of
replication.
The main limitation of this study is the small sample
size in which we performed the initial pooled GWAS screen
and individual genotyping. However, the identification of
loci known to be associated with asthma demonstrated
the validity of our study and lends credence to the findings
of novel loci. The value and innovation of this study were
to investigate the genetic factors involved in a phenotypi-
cally similar group of asthma patients. Only asthmatic and
nonasthmatic women with allergy were selected for the
pooled GWAS.This strategy is likely to bemore powerful and
to require smaller sample size in order to identify the genetic
factors underpinning asthma.
In summary, we used pooling-based GWAS to study
asthma in a homogeneous population of adult French Cana-
dian women. We then took advantage of a large-scale lung
eQTL dataset and bioinformatics tools to examine the func-
tional significance of our discoveries. Our data supported the
potential role of C3AR1 in asthma. This study also suggests
a potential role for new loci, namely, SYNE1, LINGO2, and
IFNG-AS1, in the pathogenesis of asthma.
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